

1 **Title:**

2 **Biallelic variation in the choline and ethanolamine transporter *FLVCR1* underlies a**
3 **pleiotropic disease spectrum from adult neurodegeneration to severe developmental**
4 **disorders**

5
6 **Authors:**

7 Daniel G. Calame^{1,2,3#*}; Jovi Huixin Wong^{4#}; Puravi Panda⁴; Dat Tuan Nguyen⁴; Nancy C.P.
8 Leong⁴; Riccardo Sangermano⁵; Sohil G. Patankar⁵; Mohamed Abdel-Hamid⁶; Lama AlAbdi^{7,8};
9 Sylvia Safwat⁹; Kyle P. Flannery¹⁰; Zain Dardas³; Jawid M. Fatih³; Chaya Murali³; Varun
10 Kannan¹; Timothy E. Lotze¹; Isabella Herman^{1,2,3,11}; Farah Ammouri^{11,12}; Brianna Rezich¹³;
11 Stephanie Efthymiou¹⁴; Shahryar Alavi¹⁴; David Murphy¹⁵; Zahra Firoozfar¹⁶; Mahya Ebrahimi
12 Nasab^{17,18}; Amir Bahreini^{19,20}; Majid Ghasemi²¹; Nourelhoda A. Haridy²²; Hamid Reza
13 Goldouzi²³; Fatemeh Eghbal²⁴; Ehsan Ghayoor Karimiani²⁵; Varunvenkat M. Srinivasan²⁶;
14 Vykuntaraju K. Gowda²⁶; Haowei Du³; Shalini N. Jhangiani²⁷; Zeynep Coban-Akdemir^{3,28}; Dana
15 Marafi^{3,29}; Lance Rodan^{30,31}; Sedat Isikay³²; Jill A. Rosenfeld^{3,33}; Subhadra Ramanathan³⁴;
16 Michael Staton³⁴; Kerby C. Oberg³⁵; Robin D. Clark³⁴; Catharina Wenman³⁶; Sam Loughlin³⁶;
17 Ramy Saad³⁷; Tazeen Ashraf³⁷; Alison Male³⁷; Shereen Tadros³⁷; Reza Boostani³⁸; Ghada M.H.
18 Abdel-Salam³⁹; Maha Zaki³⁹; Ebtessam Abdalla⁹; M. Chiara Manzini¹⁰; Davut Pehlivan^{1,2,3};
19 Jennifer E. Posey³; Richard A. Gibbs^{3,27}; Henry Houlden¹⁴; Fowzan S. Alkuraya^{40,41}; Kinga
20 Bujakowska⁵; Reza Maroofian¹⁴; James R. Lupski^{2,3,27,42*}; Long Nam Nguyen^{4,43-46*}

21

22 **Author Affiliations:**

- 23 1. Section of Pediatric Neurology and Developmental Neuroscience, Department of
24 Pediatrics, Baylor College of Medicine, Houston, TX, USA
25 2. Texas Children's Hospital, Houston, TX, USA
26 3. Department of Molecular and Human Genetics, Baylor College of Medicine,
27 Houston, TX, USA

- 28 4. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of
29 Singapore, Singapore 119228.
- 30 5. Ocular Genomics Institute, Department of Ophthalmology, Massachusetts Eye and Ear,
31 Harvard Medical School, Boston, MA
- 32 6. Medical Molecular Genetics Department, Human Genetics and Genome Research
33 Institute, National Research Centre, Cairo, Egypt.
- 34 7. Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia
- 35 8. Department of Translational Genomics, Center for Genomic Medicine, King Faisal
36 Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- 37 9. Department of Genetics, Medical Research Institute, Alexandria University, Alexandria,
38 Egypt
- 39 10. Department of Neuroscience and Cell Biology, Rutgers-Robert Wood Johnson Medical
40 School, Child Health Institute of New Jersey, NY, USA
- 41 11. Boys Town National Research Hospital, Boys Town, NE, USA
- 42 12. The University of Kansas Health System, Westwood, KS, USA
- 43 13. Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical
44 Center, Omaha, NE, USA
- 45 14. Department of Neuromuscular diseases, UCL Institute of Neurology, WC1N 3BG,
46 London, UK
- 47 15. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of
48 Neurology, University College London, United Kingdom
- 49 16. Palindrome, Isfahan, Iran
- 50 17. Meybod Genetic Research Center, Yazd, Iran
- 51 18. Yazd Welfare Organization, Yazd, Iran
- 52 19. KaryoGen, Isfahan, Iran
- 53 20. Department of Human Genetics, University of Pittsburgh, PA, USA
- 54 21. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
- 55 22. Department of Neurology, Faculty of Medicine, Assiut University, Assiut, Egypt
- 56 23. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences,
57 Mashhad, Iran
- 58 24. Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.
- 59 25. Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer
60 Terrace London, London, UK.
- 61 26. Department of Pediatric Neurology, Indira Gandhi Institute of Child Health, Bangalore,
62 India
- 63 27. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
- 64 28. Human Genetics Center, Department of Epidemiology, Human Genetics, and
65 Environmental Sciences, School of Public Health, The University of Texas Health
66 Science Center at Houston, Houston, TX, USA
- 67 29. Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait
- 68 30. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA
- 69 31. Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts,
70 USA
- 71 32. Gaziantep Islam Science and Technology University, Medical Faculty, Department of
72 Pediatric Neurology, Gaziantep, Turkey
- 73 33. Baylor Genetics Laboratories, Houston, TX, USA
- 74 34. Division of Genetics, Department of Pediatrics, Loma Linda University School of
75 Medicine, Loma Linda, CA, USA

- 76 35. Department of Pathology and Human Anatomy, Loma Linda University School of
77 Medicine, Loma Linda, CA, USA
78 36. Rare & Inherited Disease Laboratory, NHS North Thames Genomic Laboratory Hub,
79 Great Ormond Street Hospital for Children NHS Foundation Trust, London, WC1N 3BH,
80 UK
81 37. North East Thames Regional Genetic Service, Great Ormond Street Hospital for
82 Children NHS Foundation Trust, London, UK
83 38. Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran
84 39. Department of Clinical Genetics, Human Genetics and Genome Research Division,
85 National Research Centre, Cairo, Egypt.
86 40. Department of Translational Genomics, Center for Genomic Medicine, King Faisal
87 Specialist Hospital and Research Center, Riyadh, Saudi Arabia
88 41. Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
89 42. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
90 43. Immunology Program, Life Sciences Institute, National University of Singapore,
91 Singapore 117456.
92 44. Singapore Lipidomics Incubator (SLING), Life Sciences Institute, National University of
93 Singapore, Singapore 117456.
94 45. Cardiovascular Disease Research (CVD) Programme, Yong Loo Lin School of Medicine,
95 National University of Singapore, Singapore 117545.
96 46. Immunology Translational Research Program, Yong Loo Lin School of Medicine,
97 National University of Singapore, Singapore 117456.

98 # - these authors contributed equally.

99
100 * Corresponding authors: D.G.C. (Daniel.calame@bcm.edu); J.R.L. (jlupski@bcm.edu), L.N.
101 (bchnnl@nus.edu.sg)

102 Running Title: *FLVCR1*-related severe neurodevelopmental disorders

103

104 **Keywords:**

105 *FLVCR1*; choline; ethanolamine; neurodevelopmental disorders; neurodegeneration; multiple
106 congenital anomalies; Diamond-Blackfan anemia

107

108

109

110

111

112

113

114 **Abstract:**

115 *FLVCR1* encodes Feline leukemia virus subgroup C receptor 1 (FLVCR1), a solute
116 carrier (SLC) transporter within the Major Facilitator Superfamily. FLVCR1 is a widely expressed
117 transmembrane protein with plasma membrane and mitochondrial isoforms implicated in heme,
118 choline, and ethanolamine transport. While *Flvcr1* knockout mice die *in utero* with skeletal
119 malformations and defective erythropoiesis reminiscent of Diamond-Blackfan anemia, rare
120 biallelic pathogenic *FLVCR1* variants are linked to childhood or adult-onset neurodegeneration
121 of the retina, spinal cord, and peripheral nervous system.

122 We ascertained from research and clinical exome sequencing 27 individuals from 20
123 unrelated families with biallelic ultra-rare missense and predicted loss-of-function (pLoF)
124 *FLVCR1* variant alleles. We characterize an expansive *FLVCR1* phenotypic spectrum ranging
125 from adult-onset retinitis pigmentosa to severe developmental disorders with microcephaly,
126 reduced brain volume, epilepsy, spasticity, and premature death. The most severely affected
127 individuals, including three individuals with homozygous pLoF variants, share traits with *Flvcr1*
128 knockout mice and Diamond-Blackfan anemia including macrocytic anemia and congenital
129 skeletal malformations. Pathogenic *FLVCR1* missense variants primarily lie within
130 transmembrane domains and reduce choline and ethanolamine transport activity compared with
131 wild-type *FLVCR1* with minimal impact on FLVCR1 stability or subcellular localization. Several
132 variants disrupt splicing in a mini-gene assay which may contribute to genotype-phenotype
133 correlations. Taken together, these data support an allele-specific gene dosage model in which
134 phenotypic severity reflects residual FLVCR1 activity. This study expands our understanding of
135 Mendelian disorders of choline and ethanolamine transport and demonstrates the importance of
136 choline and ethanolamine in neurodevelopment and neuronal homeostasis.

137

138

139 **Text:**

140 Solute transport across lipid bilayers is critical for biological homeostasis and requires
141 specialized transmembrane proteins¹. The largest group of membrane transport proteins is the
142 solute carrier (SLC) superfamily. The superfamily consists of 458 genes divided into 65
143 families¹. SLC proteins transport a vast assortment of solutes including amino acids, sugars,
144 ions, nucleotides, vitamins, and neurotransmitters. Genetic variation in SLC genes influences
145 common diseases, metabolic traits, and an expanding spectrum of Mendelian disorders²⁻⁴. As
146 solute transport disorders are responsive to solute supplementation, dietary interventions, and
147 gene therapies in preclinical models and humans, they are attractive therapeutic targets⁵⁻⁷. Yet,
148 the function of most SLC genes in human biology remains poorly characterized.

149 One SLC family member associated with Mendelian neurodegenerative disorders is
150 *FLVCR1* (also known as *SLC49A1* and *MFSD7B*). First recognized as the receptor for Feline
151 Leukemia Virus Subgroup C (FeLV-C), a retrovirus which causes aplastic anemia in cats⁸,
152 *FLVCR1* is highly conserved and encodes two isoforms in humans: a full-length 555 amino acid
153 (aa) plasma membrane isoform FLVCR1a and a small mitochondrial membrane isoform
154 FLVCR1b (aa 277-555)⁹. FLVCR1 was initially described as a heme exporter in erythroid cells
155 and other cell lineages¹⁰. An essential requirement for FLVCR1 was subsequently demonstrated
156 through knockout of the mouse ortholog *Flvcr1*¹¹. Germline knockout of *Flvcr1* results in
157 embryonic lethality, absent erythropoiesis, craniofacial and limb malformations, and hepatic iron
158 accumulation, whereas neonatal deletion causes severe macrocytic anemia¹¹. Both FLVCR1
159 isoforms are required for murine viability; mice retaining FLVCR1b but lacking FLVCR1a have
160 normal erythropoiesis but develop hemorrhages, edema, and skeletal malformations⁹. The
161 physiologic significance of FLVCR1 heme transport has been called in question especially
162 considering recent evidence that FLVCR1 is a choline and ethanolamine transporter^{4,12-16}.

163 The severe anemia and craniofacial, limb and digital malformations in *Flvcr1* knockout
164 mice resemble humans with Diamond-Blackfan anemia (DBA) [MIM: 105650]^{11,17}. A further link
165 between *FLVCR1* and DBA was suggested by the observation that *FLVCR1* splicing is
166 dysregulated in erythroid cells from patients with DBA¹⁸. However, biallelic variation in *FLVCR1*
167 has not been identified in individuals with DBA, and DBA is now recognized as primarily a
168 disorder of ribosome biogenesis¹⁷. Instead, biallelic pathogenic variation in *FLVCR1* causes rare
169 recessive neurodegenerative disorders of the retina, spinal cord, and peripheral nerves:
170 posterior column ataxia with retinitis pigmentosa (PCARP) [MIM: 609033], isolated retinitis
171 pigmentosa (RP), and hereditary sensory and autonomic neuropathy (HSAN)^{19–21}. *FLVCR1*-
172 related neurodegenerative disorders can manifest from childhood into adulthood. To date, at
173 least 39 individuals from 22 families have been identified with *FLVCR1*-related
174 neurodegeneration; most have biallelic *FLVCR1* missense variants, and predicted loss-of-
175 function variants have only been identified *in trans* with missense variants (**Supplemental**
176 **Table S1**). Despite the severe multi-organ consequences of *Flvcr1* knockout in mice, extra-
177 neurological findings or severe developmental disorders have only been described in one
178 individual with biallelic *FLVCR1* variants, a compound heterozygote (c.574T>C p.Cys192Arg;
179 c.610del p.Met204Cysfs*56) with severe developmental disabilities, chronic macrocytic anemia,
180 liver disease, self-mutilation, and sensory neuropathy²¹. The precise reason(s) for the apparent
181 discrepancies between human and mouse *FLVCR1*-related phenotypes remains unclear but
182 could suggest that *FLVCR1* knockout is incompatible with human life.

183 The index case who initiated this study is a male child with severe developmental delay,
184 epileptic encephalopathy, and microcephaly (Individual 1, **Fig. 1, Fig. 2A-E, Table 1**). He was
185 born to non-consanguineous parents from a country in South Asia. He had a history of infantile
186 spasms, self-mutilation, osteomyelitis, and absent sensory nerve responses on nerve
187 conduction studies. Brain magnetic resonance imaging (MRI) showed corpus callosum thinning,

188 brainstem and pontine thinning, prominent extra-axial fluid spaces, and reduced white matter
189 volume (**Fig. 2A-E**). Uric acid and purine levels, measured to assess for Lesch-Nyhan
190 syndrome [MIM: 300322] due to the history of severe self-injury, were normal. Clinical trio
191 exome sequencing (cES) did not identify any variants in *HPRT1* nor pathogenic variants in
192 known disease genes. Hence, these cES data underwent research reanalysis through the
193 Baylor College of Medicine Genomics Research Elucidates the Genetics of Rare diseases
194 (BCM-GREGoR) which prioritized the homozygous *FLVCR1* missense variant c.1390G>A
195 p.G464S given the overlap between the patient's known sensory neuropathy and known
196 *FLVCR1*-related disorders.

197 To comprehensively characterize the phenotypic spectrum of *FLVCR1*-related disorders
198 in humans, we reanalyzed ES and genome sequencing (GS) data from the 29,766 individuals
199 within the BCM-GREGoR and Baylor Genetics clinical diagnostic databases²², utilized the online
200 matchmaking program GeneMatcher^{23,24}, and searched other research and diagnostic lab
201 datasets. We identified 27 individuals from 20 unrelated families with neurological disorders and
202 biallelic *FLVCR1* variants (**Fig. 1, Table 1**). A pedigree was not available for Individual 27, an
203 elderly woman with isolated retinitis pigmentosa and dystonia. Unlike prior reports describing
204 biallelic *FLVCR1* variants in children or adults with neurodegenerative disorders, Individuals 1-
205 17 had severe developmental disorders. Notably, three individuals with severe developmental
206 disorders had homozygous *FLVCR1* pLoF variants (Individuals 4, 15, and 17). Individuals 18-27
207 had childhood or adult-onset neurodegenerative disorders including PCARP, hereditary spastic
208 paraplegia, and RP (**Table 1**). Most families (14/20) are consanguineous by clinical history. In
209 Families 1 and 7, the same homozygous missense variant c.1390G>A p.G464S was identified.
210 Both families originate in the same country in South Asia and are unrelated. Neither family are
211 consanguineous by clinical history. Absence-of-heterozygosity (AOH), a surrogate measure
212 from ES data for runs-of-homozygosity (ROH), was calculated for Family 1; total autosomal

213 AOH was 150.1 Mb, and the variant was surrounded by a 4.9 Mb AOH block (**Supplemental**
214 **Fig. 1**)²⁵. These data suggest *FLVCR1*: c.1390G>A p.G464S may represent a South Asian
215 founder allele. Compound heterozygous variants were identified in the three non-
216 consanguineous families and segregated according to Mendelian expectations within Family 8.
217 All clinical and research data were acquired in accordance with ethical standards upon informed
218 consent and with the approval of the collaborative institutional review boards (**Supplemental**
219 **Methods**).

220 The phenotypic features of the 27 individuals are summarized in **Table 1**, **Fig. 2**, and
221 **Supplemental Table 1**. Individuals 1-17 exhibited severe developmental delay: all were non-
222 verbal and achieved no developmental motor milestones. All were microcephalic (median Z-
223 score -4.45, range -2.5 to -10.5) and had reduced brain volume on brain magnetic resonance
224 imaging (MRI). Individual 16 was microcephalic at birth (29 cm, Z-score -3.9) but was
225 normocephalic at 3 years old (50.2 cm, Z-score +1.05). Brain MRI findings varied considerably.
226 Some individuals had only a mild reduction in white matter volume, corpus callosum thinning,
227 and/or pontine and brainstem thinning (**Fig. 2E**). Others had a severe reduction in brain volume
228 with simplified gyral pattern (**Fig. 2H, J, K**). In Family 8, cystic encephalomalacia was seen in all
229 three affected siblings (**Fig. 2O-R**); cystic encephalomalacia was detected on fetal MRI
230 suggesting a very early developmental defect. Individuals 16 and 17 had only a thin rim of
231 cerebral cortex reminiscent of hydrancephaly. Another recurring MRI finding observed in
232 Individuals 1 and 3 was T2 hyperintensity of the posterior columns on spine MRI as previously
233 reported in PCARP (**Fig. 2L**). Premature death before adulthood was common (14/17).
234 Hypotonia and epilepsy were nearly universal in individuals who survived the neonatal period.
235 Other common traits include cortical visual impairment, optic disk atrophy, and spasticity.
236 Features previously associated with *FLVCR1* including RP and sensory neuropathy were
237 observed but uncommon; this could represent age-dependent penetrance due to the young age

238 of the cohort or under-ascertainment. Individuals 1 and 8 with the homozygous p.G464S variant
239 had a history of self-mutilation, osteomyelitis, and sensory neuropathy; congenital insensitivity to
240 pain was reported in Individual 3, but nerve conduction studies were not performed. Individual
241 16 also engaged in self-injurious behavior including tongue and lip biting.

242 The most profoundly affected individuals exhibited considerable phenotypic overlap with
243 *Flvcr1* knockout mice. Individuals 9-11 in Family 8 were stillborn and exhibited craniofacial, limb,
244 and digital malformations; they were recently identified in a large cohort that investigated the
245 utility of long-read whole genome sequencing²⁶ (**Fig. 2X-g, Supplemental Data**). Individual 17
246 from Family 12 died on in the neonatal period. Fetal MRI and autopsy demonstrated
247 craniofacial, limb, and digital malformations in addition to congenital heart disease, renal
248 agenesis, hepatosplenomegaly, and paper-thin cerebral cortex with hydrocephalus and multiple
249 hemorrhages (**Fig. 2X-d, Supplemental Data**). Bone marrow hematopoiesis was normal.
250 Hepatomegaly and milder digital malformations including polydactyly and arthrogyrosis were
251 also observed in other individuals with *FLVCR1*-associated severe developmental disorders.
252 Unexplained macrocytic anemia was present in 5 of 12 individuals who survived the neonatal
253 period and for whom red blood cell studies were performed. Reduced fetal movements were
254 reported in Families 8 and 11.

255 Families 13-20 had mild *FLVCR1*-related diseases including typical phenotypes
256 (PCARP, HSN, RP) as well as developmental delay and the novel phenotype hereditary
257 spastic paraplegia. While spasticity is a common feature of severe *FLVCR1*-related
258 developmental disorders, it is uncommon in mild *FLVCR1*-related disease²⁷. Two recurrent
259 variants, p.Y128N and p.I343T, were observed in unrelated Persian families. Brain MRI was not
260 performed in most instances of mild *FLVCR1*-related disease but was normal in individual 20
261 with *FLVCR1*-related sensory neuropathy, RP, and mild intellectual disability. The two siblings in
262 Family 17 were evaluated for developmental delay, microcephaly, hypotonia, and hyporreflexia.

263 There was intrafamilial variability with the younger brother exhibiting more developmental
264 impairment than the older brother (**Supplemental Fig. 2**). In Family 18, the young adult
265 asymptomatic sister of Individual 25 was also homozygous for *FLVCR1*: c.502C>G p.L168V; as
266 age of onset as late as the third or fourth decade of life has been described, this likely
267 represents age-related penetrance²⁸.

268 Twenty *FLVCR1* variants were identified within the cohort; only two,
269 c.1593+5_1593+8del and c.574T>C p.C192R were previously reported (**Table 2**)^{19,29}.
270 *FLVCR1*(NM_014053.4) consists of 10 exons and encodes a protein with 12 transmembrane
271 domains. We visualize the distribution of reported pathogenic *FLVCR1* variants within the
272 *FLVCR1*(NM_014053.4) cDNA and protein (**Fig. 3A,B**). All pathogenic *FLVCR1* variants are
273 rare and absent in the homozygous state in gnomAD v2.1.1³⁰. Most are predicted damaging by
274 multiple pathogenicity predictors and affect conserved residues (**Table 2, Supplemental Table**
275 **1**). Amino acid substitutions within *FLVCR1* transmembrane domains are predicted damaging
276 by the protein language model ESM1b³¹, and nearly all pathogenic *FLVCR1* missense variants
277 fall within well-conserved transmembrane domains (**Fig. 3B; Supplemental Fig. 4**). All *FLVCR1*
278 nonsense and frameshift variants are predicted to trigger nonsense-mediated decay (NMD)³².
279 To assess the impact of c.884-3C>G on splicing, whole blood RNA was isolated from the carrier
280 mother of Individual 16, and reverse transcriptase polymerase chain reaction (RT-PCR) was
281 performed. RT-PCR produced two bands: a larger band seen in controls and a smaller band
282 absent in controls (**Supplemental Fig. 4**). Sanger sequencing confirmed that the larger band
283 represented wild-type *FLVCR1*, whereas the smaller band represented a heterozygous deletion
284 of exon 3 (r.884_1024del, p.A295_Y341del). The deletion spans portions of transmembrane
285 domains 6 and 7 and completely removes the fourth cytoplasmic loop (**Fig. 3B**). The splicing
286 variant c.1593+5_1593+8del is strongly predicted to alter splicing by SpliceAI (donor loss Δ
287 score 0.97) and Pangolin (splice loss Δ score 0.88). A mini-gene splicing assay confirmed this

288 variant causes exon 9 skipping which is predicted to result in protein truncation
289 (r.1526_1593del; p.A509Dfs*4) (**Supplemental Fig. 5 & 9**).

290 Pathogenic missense variants are anticipated to disrupt gene function and involve more
291 highly conserved functional regions than benign missense variants within the human population
292 and non-human primates. We therefore compared pathogenicity predictions and conservation
293 metrics between *FLVCR1* missense variants identified in individuals with *FLVCR1*-related
294 disorders and *FLVCR1* missense variants present in human and primate populations in
295 gnomAD v2.1.1 and primAD v1.0 (**Fig. 3C**)^{30,33}. CADD, REVEL, MetaRNN, phyloP100way, and
296 GERP scores were all significantly greater in cases than controls. In contrast, there was no
297 difference in CADD, REVEL, or GERP scores between missense variants identified in mild
298 versus severe *FLVCR1*-related disorders (**Fig. 3D**). Comparison of the distribution of severe
299 versus mild disease-associated missense variants demonstrated that severe disease-
300 associated missense variants form a cluster within transmembrane domains 9-11 (5 of 8 severe
301 disease-associated variants vs. 0 of 15 mild disease-associated variants). Similarly, 87.5% of
302 severe disease-associated missense variants (7/8) lie within both the plasma membrane
303 isoform *FLVCR1a* and the mitochondrial isoform *FLVCR1b*, whereas only 53.3% of mild
304 disease-associated missense variants (8/15) fell within both isoforms.

305 To investigate the molecular consequence of *FLVCR1* missense variants on gene
306 function, we generated missense variants using site-directed mutagenesis of human *FLVCR1*
307 cDNA and examined each variant's choline and ethanolamine transport activity (**Fig. 4**)¹⁴.
308 Briefly, human *FLVCR1* cDNA was co-transfected into HEK293 cells along with human choline
309 kinase A (*CHKA*) or ethanolamine kinase 1 (*ETNK1*) cDNA because the sole expression of
310 *FLVCR1* cDNA only slightly increased choline or ethanolamine transport activity. HEK293 cells
311 were then incubated with [³H] choline or [¹⁴C] ethanolamine, washed, and cellular radioactivity
312 levels were measured. *CHKA* catalyzes choline phosphorylation into phosphocholine while

313 ETNK1 catalyzes ethanolamine into phosphatidylethanolamine; their co-expression along with
314 FLVCR1 greatly increases choline or ethanolamine import¹⁴. In addition to the FLVCR1
315 missense variants identified in this publication, we also examined p.Q124L and p.G219C, two
316 FLVCR1 variants recently identified in an individual with HSAN^{19,34}. These assays demonstrated
317 nearly all FLVCR1 missense variants significantly reduced choline and ethanolamine transport
318 activity relative to wild-type FLVCR1 with transport activity ranging from 0% to 55.38% (choline)
319 and 0% to 48.80%. The transport activity of two variants, p.M151V and p.D421N, was
320 comparable to wild-type FLVCR1. The p.M151V variant occurred in the homozygous state in an
321 individual within the BCM-GREGoR database. This individual had a blended developmental
322 disorder phenotype resulting from multi-locus pathogenic variation in three genes: *AP4B1*,
323 *AMPD2*, and *NOTCH2*³⁵. As the individual's phenotype is explained by other gene variants and
324 the p.M151V variant's transport activity is normal, p.M151V may represent a rare benign
325 polymorphism. The p.D421N variant was identified in compound heterozygosity with a
326 nonsense variant in Individual 3. Although p.D421N did not alter choline or ethanolamine
327 transport activity, the variant is weakly predicted to cause donor loss by SpliceAI (score 0.22). A
328 mini-gene splicing assay of this variant (c.1261G>A p.D421N) demonstrated a strong effect on
329 exon 6 skipping (**Supplemental Fig. 5 & 6**). The phenotypic overlap of Individual 3 with other
330 severe *FLVCR1* cases and the presence of typical *FLVCR1* features including RP and posterior
331 column T2 hyperintensity supports the variant's pathogenicity. Another missense variant in the
332 same exon (c.1235G>A p.G412A) also showed a strong effect on exon 6 skipping in addition to
333 its effect on choline and ethanolamine transport (**Supplemental Fig. 5 & 6**). Western blot
334 analysis of HEK293 cells overexpressing wild-type and variant FLVCR1 showed similar levels of
335 FLVCR1 protein indicating that FLVCR1 missense variants do not impact protein stability (**Fig.**
336 **4**). Immunostaining demonstrates FLVCR1 missense variants localize to the plasma membrane
337 like wild-type FLVCR1; only p.G412A exhibited abnormal intracellular accumulation (**Fig. 4**). As
338 we previously characterized the choline transport activity of all *FLVCR1* missense variants

339 reported in the literature³⁶, we compared transport activity between mild and severe phenotype-
340 associated variants but found no significant difference (mean choline transport activity as a
341 percentage of wild-type *FLVCR1*: mild phenotypes, 34.3 ± 21.9 ; severe phenotypes, 35.5 ± 21.9 ;
342 $p=0.9222$).

343 Here, we demonstrate rare genetic variation in the choline and ethanolamine transporter
344 gene *FLVCR1* causes a broad and pleiotropic recessive disease spectrum ranging from adult
345 neurodegeneration to severe developmental disorders. Choline is an essential nutrient which
346 plays an integral role in methyl group metabolism, phosphatidylcholine (PC) synthesis via the
347 Kennedy pathway, and acetylcholine synthesis³⁷. While *de novo* choline synthesis occurs in the
348 liver through the phosphatidylethanolamine *N*-methyltransferase pathway, this pathway is
349 inadequate to meet the needs of the human organism³⁷. Choline is found in animal products,
350 cruciferous vegetables, and beans³⁷. The dietary intake of choline in most individuals in the
351 United States and Europe falls below the United States Institute of Medicine's adequate intake
352 level^{37,38}. Choline insufficiency is particularly common in low-income countries, and choline is
353 neglected in nutrient-fortified food aid³⁹. Furthermore, individual dietary requirements vary
354 considerably due to multiple factors including genotype, sex, developmental stage, and dietary
355 intake of vitamins involved in methyl group metabolism including folate and B12⁴⁰. Single
356 nucleotide polymorphisms in genes involved in the phosphatidylethanolamine *N*-
357 methyltransferase pathway, folate and methyl group metabolism, and choline transport including
358 *PEMT*, *MTHFR*, *MTR*, *MTRR*, and *SLC44A1* have been shown to modulate choline
359 requirements and risk of choline deficiency⁴⁰. Similarly, ethanolamine cannot be synthesized in
360 humans and is a precursor for phosphatidylethanolamine (PE) synthesis via the Kennedy
361 pathway⁴¹. PE and PC are abundant membrane phospholipids required for membrane integrity,
362 cell division, and mitochondrial respiratory function.

363 Choline is required for normal neurodevelopment⁴². Maternal choline deficiency impairs
364 hippocampal development as well as neuronal progenitor cell and retinal progenitor cell
365 expansion and differentiation in mouse embryos^{43,44}. Choline deficiency also causes anemia,
366 liver disease, growth retardation, and immune deficiency⁴⁵⁻⁴⁷. Neurodevelopment is also
367 disrupted by defective choline uptake⁴⁸. Pathogenic variation in *SLC5A7*, the gene encoding a
368 high affinity choline transporter expressed in cholinergic neurons, causes two
369 neurodevelopmental disorders: autosomal recessive (AR) presynaptic congenital myasthenic
370 syndrome 20 [MIM: 617143] and autosomal dominant (AD) distal hereditary motor
371 neuronopathy [MIM: 158580]^{49,50}. Similarly, pathogenic variation in *SLC44A1*, a gene predicted
372 to encode the low affinity choline transporter CTL1, causes AR childhood-onset
373 neurodegeneration with ataxia, tremor, optic atrophy, and cognitive decline [MIM: 618868]⁵¹.
374 Finally, the protein encoded by closely related gene *FLVCR2* is expressed at the blood-brain
375 barrier and transports choline and ethanolamine^{16,52}. Pathogenic variation in *FLVCR2* causes
376 Fowler syndrome, a severe AR disorder characterized by proliferative vasculopathy,
377 hydranencephaly, fetal akinesia deformation sequence, and prenatal lethality [MIM: 225790]⁵³.
378 The identification of *FLVCR1* as a neurodevelopmental choline and ethanolamine transport
379 disorder further reinforces the critical role of choline and ethanolamine in brain development.
380 Additionally, the identification of multiple neurodevelopmental choline and ethanolamine
381 transport disorders demonstrates considerable complexity to choline and ethanolamine
382 regulation within the developing brain and warrants further study. Therapeutic choline and
383 ethanolamine supplementation has not been attempted in patients with choline and
384 ethanolamine transport disorders but could in theory be efficacious as in riboflavin transporter
385 deficiency⁶. The existence of multiple choline transporters allows for alternative routes for
386 choline uptake¹, and supplementation could potentially boost choline intake through
387 hypomorphic transporters. Randomized controlled trials of choline supplementation in fetal
388 alcohol syndrome have shown choline supplementation is well-tolerated and can have beneficial

389 neurocognitive effects^{54,55}. Measurement of choline and ethanolamine levels in biospecimens
390 from individuals with *FLVCR1*-related disorders is needed to inform choline and/or ethanolamine
391 supplementation as a potential therapeutic modality.

392 Based on these findings, we propose an allele-specific gene dosage model in which
393 disease severity is a function of residual *FLVCR1* activity. This proposal stems from three key
394 observations. First, we identified three individuals with severe developmental disorders and
395 homozygous *FLVCR1* pLoF variants. These individuals are thus genetically equivalent to *Flvcr1*
396 knockout mice and zebrafish, which also exhibit severe developmental phenotypes^{11,56}. Biallelic
397 pLoF *FLVCR1* variants have not been identified in individuals with milder *FLVCR1*-related
398 phenotypes like PCARP; nearly all reported individuals instead have biallelic missense variants.
399 Second, we show most pathogenic *FLVCR1* missense variants reduce but do not completely
400 eliminate choline and ethanolamine transport and thus likely represent hypomorphic alleles³⁶.
401 *Flvcr1* was previously shown to exhibit highest central nervous system expression in the retina
402 followed by the posterior column of the spinal cord and cerebellum; this may parsimoniously
403 explain the susceptibility of these tissues to mild hypomorphic alleles¹⁹. Third, we observe
404 evidence of complex compound inheritance in which *FLVCR1* variants may contribute to mild
405 phenotypes in homozygosity but severe phenotypes in compound heterozygosity with a more
406 severe variant (e.g., *FLVCR1* p.C192R) or severe phenotypes in homozygosity but mild
407 phenotypes when paired with a less deleterious variant (e.g., *FLVCR1*
408 c.1593+5_1593+8del)^{19,21,29}. The allele-specific gene dosage model is well-described in
409 recessive disorders but can confound diagnostic personalized genome analysis when the
410 clinically reported phenotype diverges substantially from the disease trait clinical synopsis
411 provided in the literature or online databases like Online Mendelian Inheritance in Man (OMIM).
412 Indeed, the severely affected individuals reported here had all undergone clinical or research
413 exome or genome sequencing which identified the reported *FLVCR1* variants, yet in each case

414 the variants were previously felt either non-contributory or of uncertain significance given the
415 apparent phenotypic mismatch. Such false assumptions illustrate the importance of
416 incorporating model organism data into personalized genome analysis for rare diseases and the
417 need to anticipate more severe and milder phenotypes associated with each disease gene locus
418 to maximize the yield of diagnostic genetic testing.

419 We did not observe a correlation between *FLVCR1* missense variant choline transport
420 activity and phenotypic severity in our functional assay. There are several possible
421 explanations. First, our choline transport assay may lack the sensitivity to discriminate between
422 mild and severe phenotype-associated variants. As the transport assay is reliant on
423 overexpression of *FLVCR1* cDNA, it is insensitive to splicing defects. Indeed, we demonstrate
424 through mini-gene splicing assays that several *FLVCR1* single nucleotide variants and indels
425 disrupt splicing (**Supplemental Figures 5-9**). Second, the cellular phenotype assessed by the
426 choline transport assay must be distinguished from the organismal phenotypes characterized in
427 humans with pathogenic *FLVCR1* variation. Third, *FLVCR1* was found to transport additional
428 ligands like ethanolamine in both this study and previous studies¹⁴. While a reduction in both
429 choline and ethanolamine transport was observed with most variants, some like p.S305R had a
430 more severe impact on ethanolamine than choline transport. Fourth, as both plasma membrane
431 and mitochondrial isoforms *FLVCR1a* and *FLVCR1b* are required for murine viability⁹, a
432 missense variant involving both isoforms may have a greater phenotypic impact than one only
433 impacting the plasma membrane isoform *FLVCR1a*. In line with this hypothesis, we observed
434 nearly all severe disease associated *FLVCR1* missense variants are predicted to impact both
435 isoforms. Another possibility is maternal and/or fetal deficiency of choline, ethanolamine, folate,
436 and/or B12 due to poor dietary intake or maternal-fetal genotypes could act as phenotypic
437 modifiers⁴⁰. Finally, it is important to note the phenotypes associated with homozygous first
438 exon frameshifts in Individuals 4 and 15 were not as severe as those seen in Individual 17 with

439 the homozygous exon 4 nonsense variant nor in individuals 12-14 with the homozygous splice
440 site variant c.1593+5_1593+8del. This defines a gene polarity effect⁵⁷. One possible explanation
441 is first exon pLoF variants may not represent true null alleles. First exon premature termination
442 codons (PTCs) can escape NMD and generate a functional or partially functional truncated
443 protein if a downstream methionine allows for in-frame translation re-initiation⁵⁸.

444 In summary, our report reveals a broad and pleiotropic phenotypic spectrum resulting
445 from biallelic *FLVCR1* variants; these range from adult neurodegeneration to severe
446 developmental disorders with variable anemia and skeletal malformations. Combined with
447 recent studies demonstrating *FLVCR1* encodes a choline and ethanolamine transporter^{4,13,16,36},
448 these data suggest choline and ethanolamine transport into the central and peripheral nervous
449 systems is essential to prevent neurodegeneration and required for neurodevelopment. The
450 observation that the most severe *FLVCR1*-related phenotypes cause stillbirth and resemble
451 Diamond-Blackfan anemia establishes *FLVCR1* should be considered in the differential
452 diagnosis of recurrent miscarriage, multiple congenital anomalies, and severe Diamond-
453 Blackfan anemia-like phenotypes. Further studies are required to understand the impact of gene
454 x environmental (GxE) interactions on *FLVCR1*-related phenotypes and the therapeutic
455 implications of choline or ethanolamine supplementation in *FLVCR1*-related diseases.

456

457 **Figure Legends:**

458 **Figure 1: Pedigrees of families with *FLVCR1*-related developmental and**
459 **neurodegenerative disorders.**

460 **Per medrxiv requirements, this figure was removed but is available upon request to the**
461 **corresponding authors.**

462 Pedigrees of families with *FLVCR1*-related diseases. Genotype is indicated above each
463 pedigree and below each family member. *A* indicates wild-type *FLVCR1* allele, *a* indicates

464 *FLVCR1* variant allele 1, and *a'* indicates *FLVCR1* variant allele 2; specific variants differ from
465 one pedigree to the next. Red shading indicates severe *FLVCR1*-related disease (microcephaly,
466 brain atrophy, severe developmental disabilities), whereas light blue shading indicates relatively
467 milder neurological *FLVCR1*-related disease (posterior column ataxia with retinitis pigmentosa,
468 hereditary sensory and autonomic neuropathy, isolated retinitis pigmentosa, or hereditary
469 spastic paraplegia). Gray shading indicates individuals suspected of possibly having a different
470 genetic syndrome characterized by neonatal demise, hypotonia, and arthrogryposis.

471
472 **Figure 2: Phenotypic features of *FLVCR1*-related developmental and neurodegenerative**
473 **disorders**

474 Photographs and magnetic resonance imaging (MRI) from each family are divided into separate
475 boxes bordered by thin black lines. **Per medrxiv requirements, patient photographs have**
476 **been removed but are available upon request to the corresponding authors.**

477 **A-E)** Images of Individual 1 (I-1), Family 1 with homozygous *FLVCR1* p.G464S variant. A-D
478 show examples of self-mutilation including foot, ear, and arm ulcerations (yellow arrowheads)
479 and digital amputation (red arrowhead). E shows sagittal T1-weighted brain MRI. Pontine
480 thinning is indicated with yellow arrow.

481 **F)** Image of Individual 8 (I-8), Family 7 with homozygous *FLVCR1* p.G464S variant. Self-
482 mutilation and digital amputation of the hand is shown.

483 **G, H)** Images of Individual 2 (I-2), Family 2. G shows patient with triangular facies, microcephaly
484 and severe developmental delay. H shows axial T2-weighted brain MRI demonstrating severe
485 reduction in cerebral brain volume and a simplified gyral pattern.

486 **I, J)** Images of Individual 5 (I-5), Family 5. I shows patient with microcephaly, broad nasal
487 bridge, widely spaced eyes, and severe developmental delay. J shows axial T1-weighted brain
488 MRI, demonstrating severe reduction in cerebral brain volume and a simplified gyral pattern.

489 **K, L)** Images of Individual 3 (I-3), Family 3. K shows axial T2-weighted brain MRI with severe
490 reduction in cerebral brain volume. L shows T2-weighted cervical spine MRI demonstrating
491 posterior column T2 signal hyperintensity (red arrow).

492 **M-R)** Images of Individuals 10 and 11 (I-10 and I-11), Family 8. M and N show individuals 10
493 and 11. Photographs demonstrating microcephaly, severe developmental delay, broad nasal
494 bridge, and tracheostomy secondary to respiratory failure. O-R show axial T1-weighted brain
495 MRI from Individual 11 demonstrating reduction in cerebral brain volume with relative cerebellar
496 sparing and cystic encephalomalacia (red arrows).

497 **S-U)** Images of Individual 7 (I-7), Family 6. Images show axial T2-weighted brain MRI with
498 reduction in cerebral brain volume.

499 **V, W)** Images of Individual 16 (I-16), Family 11. V and W show coronal T2-weighted brain MRI
500 and axial T1-weighted brain MRI respectively demonstrating a severe reduction in brain volume
501 with hydrocephalus *ex vacuo*.

502 **X-d)** Images of Individual 17 (I-17), Family 12. X shows irregular undulation of the ear lobe. Y
503 shows the left foot with ankle dislocation and absence of the great toe, 2nd toe, and 3rd toe. Z
504 shows the right foot demonstrating cleft foot, absence of the 2nd toe, syndactyly of toes 3-4, and
505 proximal displacement of the great toe. a is a full body radiograph demonstrating ten ribs, long
506 limbs, absent left tibia (red arrow), and bilateral ectrodactyly of the feet. b-d are fetal T2-
507 weighted MRI images performed at 28 weeks gestation. b shows hydrocephalus with absence
508 of midline structures (blue arrow) and hypertrophic kidney with pelviectasis (red arrow). c shows
509 hydrocephalus with absence of some midline structures (red arrow) and thinning of the cortical

510 mantle (blue arrow). d shows severe hydrocephalus with thinning of the cortical mantle (red
511 arrow), small cerebellum and brainstem (blue arrow), and left kidney hypertrophy with absence
512 of the right kidney (yellow arrow).

513 e-g) Images of Individual 13 (I-13), Family 9. Postmortem images of Individual 13 (c-e) show
514 joint contractures, long tapering fingers. absent right thumb, hypoplastic left thumb,
515 microcephaly, and cleft lip and palate.

516 **Figure 3: Summary of the *FLVCR1* allelic series**

517 **A)** Model of protein-coding portions of human *FLVCR1* cDNA (NM_014053.4) showing location
518 of novel and previously published start loss variants, splicing variants, nonsense variants, and
519 frameshift variant alleles. Start loss and splicing variants are indicated by arrowheads above the
520 model. Nonsense and frameshift variants are indicated by arrowheads below the model. Red
521 arrowheads show variants associated with severe phenotypes, whereas light blue shading
522 indicates the relatively milder neurological disease.

523 **B)** Model of human FLVCR1 protein (Uniprot entry Q9Y5Y0) showing location of novel and
524 previously published missense variants. Light gray rectangles indicate transmembrane domains,
525 dark gray rectangles indicate intracellular domains, and dark blue rectangles indicate
526 extracellular domains. Red ball and sticks indicate severe phenotypes, whereas light blue ball
527 and sticks indicate mild phenotypes. Portions of FLVCR1 found within the plasma membrane
528 isoform FLVCR1a and mitochondrial isoform FLVCR1b are indicated below the figure in green
529 and purple, respectively. Red box indicates region deleted due to c.884-3C>G (r.884_1024del,
530 p.A295_Y341del). ESM1b pathogenicity predictions are shown above the model. Increasing
531 likelihood of pathogenicity is reflected by the blue (low) to yellow (high) gradient.

532 **C)** Comparison of pathogenicity predictions (CADD, REVEL, MetaRNN) and conservation
533 metrics (phyloP100way, GERP) between novel and previously reported pathogenic *FLVCR1*

534 variants and all variants within gnomAD v3.1.2 (76,156 human samples, 189 variants) and
535 primateseq v1.0 (811 primate samples from 236 primate species, 209 variants). * $p < 0.05$,
536 unpaired t test with Welch's correction.

537 **D)** Comparison of pathogenicity predictions (CADD, REVEL) and conservation metric (GERP)
538 between mild and severe *FLVCR1*-related phenotypes. Differences in transmembrane domains
539 9-11 and isoform clustering of *FLVCR1* variants between mild and severe phenotypes is also
540 displayed. Gray = variants located outside transmembrane domains 9-11, black = variants
541 located inside transmembrane domains 9-11, purple = variants located inside mitochondrial
542 isoform FLVCR1b, green = variants located inside plasma membrane isoform FLVCR1a but not
543 FLVCR1b. ns = not significant, TM = transmembrane.

544

545 **Figure 4: Pathogenic missense variation in *FLVCR1* reduces choline and ethanolamine**
546 **transport**

547 **A-B)** Choline transport activity of the *FLVCR1* missense variants expressed as absolute values
548 (DPM/well) or as percentage of wildtype (WT) *FLVCR1*. These missense variants and WT
549 human *FLVCR1* (h*FLVCR1*) were co-expressed with choline kinase alpha (CHKA) in HEK293
550 cells for activity assay with [³H] choline. Mock was transfected with CHKA alone. Experiments
551 were performed at least twice in triplicates. Data are expressed as mean \pm SD. **** $P < 0.0001$;
552 One-way ANOVA for A-B. ns, not significant.

553 **C-D)** Ethanolamine transport activity of the *FLVCR1* missense variants expressed as absolute
554 values (DPM/well) or as percentage of WT *FLVCR1*. These missense variants and WT human
555 *FLVCR1* were co-expressed with ethanolamine kinase 1 (ETNK1) in HEK293 cells for activity
556 assay with [¹⁴C] ethanolamine. Mock was transfected with ETNK1 alone. Experiments were

557 performed at least twice in triplicates. Data are expressed as mean \pm SD. ****P<0.0001; One-
558 way ANOVA for C-D. ns, not significant.

559 **E)** Western blot analysis of HEK293 cells overexpressed with WT or hFLVCR1 variants. Red
560 vertical arrowhead marks $M_r = 59$ kD migration of FLVCR1; GAPDH loading control shown
561 below.

562 **F)** Immunostaining of WT or hFLVCR1 mutants overexpressed in HEK293 cells. Vertical yellow
563 horizontal bar shows image scale. Arrows (yellow) show plasma membrane, where membrane
564 GFP was used as a marker. Arrowheads show intracellular signals of hFLVCR1.

565

566 **Web Resources**

567 Online Mendelian Inheritance in Man, <http://www.omim.org>

568 gnomAD Browser, <https://gnomad.broadinstitute.org/>

569 Baylor College of Medicine Human Genome Sequencing Center, <https://www.hgsc.bcm.edu>

570 Baylor College of Medicine Lupski Lab, <https://github.com/BCM-Lupskilab>

571 CADD, <https://cadd.gs.washington.edu/>

572 SpliceAI and Pangolin, <https://spliceailookup.broadinstitute.org/>

573 primAD Browser, <https://primad.basespace.illumina.com/>

574

575 **Data Availability**

576 All data described in this study are provided within the article and Supplementary Material. Raw
577 sequencing data and de-identified clinical data are available from the corresponding authors
578 upon request.

579

580 **Acknowledgements**

581 This study was supported in part by the U.S. National Human Genome Research Institute
582 (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for
583 Mendelian Genomics (BHCMG, UM1 HG006542, J.R.L.); NHGRI grant as part of the GREGoR
584 Consortium (U01 HG011758 to J.E.P., J.R.L., and R.A.G.); NHGRI grant to Baylor College of
585 Medicine Human Genome Sequencing Center (U54HG003273 to R.A.G.); U.S. National
586 Institute of Neurological Disorders and Stroke (NINDS) (R35NS105078 to J.R.L.); Muscular
587 Dystrophy Association (MDA) (512848 to J.R.L.); Singapore Ministry of Education grants
588 (T2EP30221-0012, T2EP30123-0014, and NUHSRO/2022/067/T1 to L.N.N.); and Spastic
589 Paraplegia Foundation Research Grant to J.R.L. D.P. was supported by a NINDS 1K23
590 NS125126-01A1 and Rett Syndrome Research Trust fellowship award from International Rett
591 Syndrome Foundation (IRSF grant #3701-1). D.G.C. was supported by NIH Medical Genetics
592 Research Fellowship Program (T32 GM007526), the Chao Physician Scientist Award, the Child
593 Neurologist Career Development Program K12, and MDA Development Grant (873841). K.M.B
594 was supported by the GREGoR Consortium Research Grant from the GREGoR Data
595 Coordinating Center (U24HG011746 to KMB); Foundation Fighting Blindness (EGI-GE-1218-
596 0753-UCSD to KMB), Iraty Award 2023, Lions Foundation, Research to Prevent Blindness, and
597 NEI: P30EY014104 (MEEI core support).

598

599 **Ethics Declaration**

600 This study adheres to the principles in the Declaration of Helsinki. The study was approved by
601 Baylor College of Medicine Institutional Review Board (IRB) protocol H-29697. Informed
602 consent including consent to have the results of this research work published was obtained from
603 all participants as required by the IRB.

604

605 **Potential Conflict of Interest**

606 J.R.L. has stock ownership in 23andMe, is a paid consultant for Genome International, and is a
607 co-inventor on multiple United States and European patents related to molecular diagnostics for
608 inherited neuropathies, eye diseases, genomic disorders, and bacterial genomic fingerprinting.
609 The Department of Molecular and Human Genetics at Baylor College of Medicine receives
610 revenue from clinical genetic testing conducted at Baylor Genetics (BG) Laboratories. Other
611 authors have no potential conflicts to disclose.

612

613 **References:**

- 614 1. Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier
615 proteins. *FEBS J.* 2021;288(9):2784-2835. doi:10.1111/febs.15531
- 616 2. Marafi D, Fatih JM, Kaiyrzhanov R, et al. Biallelic variants in SLC38A3 encoding a glutamine
617 transporter cause epileptic encephalopathy. *Brain.* 2022;145(3):909-924.
618 doi:10.1093/brain/awab369
- 619 3. Saida K, Maroofian R, Sengoku T, et al. Brain monoamine vesicular transport disease
620 caused by homozygous SLC18A2 variants: A study in 42 affected individuals. *Genet Med.*
621 2023;25(1):90-102. doi:10.1016/j.gim.2022.09.010
- 622 4. Kenny TC, Khan A, Son Y, et al. Integrative genetic analysis identifies FLVCR1 as a
623 plasma-membrane choline transporter in mammals. *Cell Metab.* 2023;35(6):1057-1071.e12.
624 doi:10.1016/j.cmet.2023.04.003
- 625 5. Klepper J, Akman C, Armeno M, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the
626 art in 2020 and recommendations of the international Glut1DS study group. *Epilepsia Open.*
627 2020;5(3):354-365. doi:10.1002/epi4.12414
- 628 6. O'Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and
629 pathomechanisms of human riboflavin transporter deficiency. *J Inherit Metab Dis.*
630 2019;42(4):598-607. doi:10.1002/jimd.12053
- 631 7. Mathiesen BK, Miyakoshi LM, Cederroth CR, et al. Delivery of gene therapy through a
632 cerebrospinal fluid conduit to rescue hearing in adult mice. *Sci Transl Med.*
633 2023;15(702):eabq3916. doi:10.1126/scitranslmed.abq3916
- 634 8. Tailor CS, Willett BJ, Kabat D. A putative cell surface receptor for anemia-inducing feline
635 leukemia virus subgroup C is a member of a transporter superfamily. *J Virol.*
636 1999;73(8):6500-6505. doi:10.1128/JVI.73.8.6500-6505.1999

- 637 9. Chiabrando D, Marro S, Mercurio S, et al. The mitochondrial heme exporter FLVCR1b
638 mediates erythroid differentiation. *J Clin Invest*. 2012;122(12):4569-4579.
639 doi:10.1172/JCI62422
- 640 10. Quigley JG, Yang Z, Worthington MT, et al. Identification of a human heme exporter that is
641 essential for erythropoiesis. *Cell*. 2004;118(6):757-766. doi:10.1016/j.cell.2004.08.014
- 642 11. Keel SB, Doty RT, Yang Z, et al. A heme export protein is required for red blood cell
643 differentiation and iron homeostasis. *Science*. 2008;319(5864):825-828.
644 doi:10.1126/science.1151133
- 645 12. Ponka P, Sheftel AD, English AM, Scott Bohle D, Garcia-Santos D. Do Mammalian Cells
646 Really Need to Export and Import Heme? *Trends Biochem Sci*. 2017;42(5):395-406.
647 doi:10.1016/j.tibs.2017.01.006
- 648 13. Tsuchiya M, Tachibana N, Nagao K, Tamura T, Hamachi I. Organelle-selective click labeling
649 coupled with flow cytometry allows high-throughput CRISPR screening of genes involved in
650 phosphatidylcholine metabolism. Published online April 18, 2022:2022.04.18.488621.
651 doi:10.1101/2022.04.18.488621
- 652 14. Ha HTT, Sukumar VK, Chua JWB, et al. Mfsd7b facilitates choline transport and missense
653 mutations affect choline transport function. *Cell Mol Life Sci*. 2023;81(1):3.
654 doi:10.1007/s00018-023-05048-4
- 655 15. Son Y, Kenny TC, Khan A, Birsoy K, Hite RK. Structural basis of lipid head group entry to
656 the Kennedy pathway by FLVCR1. *BioRxiv Prepr Serv Biol*. Published online September 28,
657 2023:2023.09.28.560019. doi:10.1101/2023.09.28.560019
- 658 16. Ri K, Weng TH, Cabezudo AC, et al. Structural and mechanistic insights into human choline
659 and ethanolamine transport. Published online December 19, 2023:2023.09.15.557925.
660 doi:10.1101/2023.09.15.557925
- 661 17. Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. *Blood*.
662 2020;136(11):1262-1273. doi:10.1182/blood.2019000947
- 663 18. Rey MA, Duffy SP, Brown JK, et al. Enhanced alternative splicing of the FLVCR1 gene in
664 Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for
665 erythropoiesis. *Haematologica*. 2008;93(11):1617-1626. doi:10.3324/haematol.13359
- 666 19. Rajadhyaksha AM, Elemento O, Puffenberger EG, et al. Mutations in FLVCR1 cause
667 posterior column ataxia and retinitis pigmentosa. *Am J Hum Genet*. 2010;87(5):643-654.
668 doi:10.1016/j.ajhg.2010.10.013
- 669 20. Kuehlewein L, Schöls L, Llavona P, et al. Phenotypic spectrum of autosomal recessive
670 retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1
671 gene. *Graefes Arch Clin Exp Ophthalmol*. 2019;257(3):629-638. doi:10.1007/s00417-018-
672 04233-7
- 673 21. Chiabrando D, Castori M, di Rocco M, et al. Mutations in the Heme Exporter FLVCR1
674 Cause Sensory Neurodegeneration with Loss of Pain Perception. *PLoS Genet*.
675 2016;12(12):e1006461. doi:10.1371/journal.pgen.1006461

- 676 22. Calame DG, Guo T, Wang C, et al. Monoallelic variation in DHX9, the gene encoding the
677 DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth
678 disease. *Am J Hum Genet.* 2023;110(8):1394-1413. doi:10.1016/j.ajhg.2023.06.013
- 679 23. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for
680 connecting investigators with an interest in the same gene. *Hum Mutat.* 2015;36(10):928-
681 930. doi:10.1002/humu.22844
- 682 24. Wohler E, Martin R, Griffith S, et al. PhenoDB, GeneMatcher and VariantMatcher, tools for
683 analysis and sharing of sequence data. *Orphanet J Rare Dis.* 2021;16(1):365.
684 doi:10.1186/s13023-021-01916-z
- 685 25. Coban-Akdemir Z, Song X, Ceballos FC, et al. De novo mutation and identity-by-descent
686 drive disease haplotypes, biallelic traits and multilocus pathogenic variation. Published
687 online July 27, 2022:2020.04.27.064824. doi:10.1101/2020.04.27.064824
- 688 26. AlAbdi L, Shamseldin HE, Khouj E, et al. Beyond the exome: utility of long-read whole
689 genome sequencing in exome-negative autosomal recessive diseases. *Genome Med.*
690 2023;15(1):114. doi:10.1186/s13073-023-01270-8
- 691 27. Vaughan DP, Costello DJ. Extending the phenotype of posterior column ataxia with retinitis
692 pigmentosa caused by variants in FLVCR1. *Am J Med Genet A.* 2022;188(4):1259-1262.
693 doi:10.1002/ajmg.a.62612
- 694 28. Li Z, Li Y, Chu X, et al. Novel mutations in FLVCR1 cause tremors, sensory neuropathy with
695 retinitis pigmentosa. *Neuropathol Off J Jpn Soc Neuropathol.* Published online July 19,
696 2023. doi:10.1111/neup.12936
- 697 29. Shaibani A, Wong LJ, Wei Zhang V, Lewis RA, Shinawi M. Autosomal recessive posterior
698 column ataxia with retinitis pigmentosa caused by novel mutations in the FLVCR1 gene. *Int*
699 *J Neurosci.* 2015;125(1):43-49. doi:10.3109/00207454.2014.904858
- 700 30. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified
701 from variation in 141,456 humans. *Nature.* 2020;581(7809):434-443. doi:10.1038/s41586-
702 020-2308-7
- 703 31. Brandes N, Goldman G, Wang CH, Ye CJ, Ntranos V. Genome-wide prediction of disease
704 variant effects with a deep protein language model. *Nat Genet.* 2023;55(9):1512-1522.
705 doi:10.1038/s41588-023-01465-0
- 706 32. Coban-Akdemir Z, White JJ, Song X, et al. Identifying Genes Whose Mutant Transcripts
707 Cause Dominant Disease Traits by Potential Gain-of-Function Alleles. *Am J Hum Genet.*
708 2018;103(2):171-187. doi:10.1016/j.ajhg.2018.06.009
- 709 33. Gao H, Hamp T, Ede J, et al. The landscape of tolerated genetic variation in humans and
710 primates. *Science.* 2023;380(6648):eabn8153. doi:10.1126/science.abn8197
- 711 34. Suthar R, Sharawat IK, Eggermann K, et al. Hereditary Sensory and Autonomic
712 Neuropathy: A Case Series of Six Children. *Neurol India.* 2022;70(1):231.
713 doi:10.4103/0028-3886.338691

- 714 35. Karaca E, Posey JE, Akdemir ZC, et al. Phenotypic expansion illuminates multilocus
715 pathogenic variation. *Genet Med*. 2018;20(12):1528-1537. doi:10.1038/gim.2018.33
- 716 36. Ha HTT, Sukumar VK, Chua JWB, et al. Mfsd7b facilitates choline uptake and missense
717 mutations affect choline transport function. Published online September 30,
718 2023:2023.09.30.560304. doi:10.1101/2023.09.30.560304
- 719 37. Zeisel SH, Klatt KC, Caudill MA. Choline. *Adv Nutr*. 2018;9(1):58-60.
720 doi:10.1093/advances/nmx004
- 721 38. Vennemann FBC, Ioannidou S, Valsta LM, et al. Dietary intake and food sources of choline
722 in European populations. *Br J Nutr*. 2015;114(12):2046-2055.
723 doi:10.1017/S0007114515003700
- 724 39. May T, Caudill M, Manary M. Is There Enough Choline for Children in Food Aid? *JAMA*
725 *Pediatr*. 2023;177(3):223-224. doi:10.1001/jamapediatrics.2022.5543
- 726 40. Ganz AB, Klatt KC, Caudill MA. Common Genetic Variants Alter Metabolism and Influence
727 Dietary Choline Requirements. *Nutrients*. 2017;9(8):837. doi:10.3390/nu9080837
- 728 41. Patel D, Witt SN. Ethanolamine and Phosphatidylethanolamine: Partners in Health and
729 Disease. *Oxid Med Cell Longev*. 2017;2017:4829180. doi:10.1155/2017/4829180
- 730 42. Zeisel SH, Niculescu MD. Perinatal choline influences brain structure and function. *Nutr*
731 *Rev*. 2006;64(4):197-203. doi:10.1111/j.1753-4887.2006.tb00202.x
- 732 43. Trujillo-Gonzalez I, Friday WB, Munson CA, et al. Low availability of choline in utero disrupts
733 development and function of the retina. *FASEB J*. 2019;33(8):9194-9209.
734 doi:10.1096/fj.201900444R
- 735 44. Wang Y, Surzenko N, Friday WB, Zeisel SH. Maternal dietary intake of choline in mice
736 regulates development of the cerebral cortex in the offspring. *FASEB J*. 2016;30(4):1566-
737 1578. doi:10.1096/fj.15-282426
- 738 45. Alexander HD, Engel RW. The importance of choline in the prevention of nutritional edema
739 in rats fed low-protein diets. *J Nutr*. 1952;47(3):361-374. doi:10.1093/jn/47.3.361
- 740 46. Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans.
741 *FASEB J Off Publ Fed Am Soc Exp Biol*. 1991;5(7):2093-2098.
- 742 47. May T, de la Haye B, Nord G, et al. One-carbon metabolism in children with marasmus and
743 kwashiorkor. *EBioMedicine*. 2022;75:103791. doi:10.1016/j.ebiom.2021.103791
- 744 48. Wortmann SB, Mayr JA. Choline-related-inherited metabolic diseases—A mini review. *J*
745 *Inherit Metab Dis*. 2019;42(2):237-242. doi:10.1002/jimd.12011
- 746 49. Barwick KES, Wright J, Al-Turki S, et al. Defective presynaptic choline transport underlies
747 hereditary motor neuropathy. *Am J Hum Genet*. 2012;91(6):1103-1107.
748 doi:10.1016/j.ajhg.2012.09.019

- 749 50. Bauché S, O'Regan S, Azuma Y, et al. Impaired Presynaptic High-Affinity Choline
750 Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea. *Am J Hum*
751 *Genet.* 2016;99(3):753-761. doi:10.1016/j.ajhg.2016.06.033
- 752 51. Fagerberg CR, Taylor A, Distelmaier F, et al. Choline transporter-like 1 deficiency causes a
753 new type of childhood-onset neurodegeneration. *Brain J Neurol.* 2020;143(1):94-111.
754 doi:10.1093/brain/awz376
- 755 52. Nguyen XTA, Le TNU, Ha HTT, et al. MFSD7c functions as a transporter of choline at the
756 blood-brain barrier. Published online October 3, 2023:2023.10.03.560597.
757 doi:10.1101/2023.10.03.560597
- 758 53. Meyer E, Ricketts C, Morgan NV, et al. Mutations in FLVCR2 are associated with
759 proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler
760 syndrome). *Am J Hum Genet.* 2010;86(3):471-478. doi:10.1016/j.ajhg.2010.02.004
- 761 54. Wozniak JR, Fuglestad AJ, Eckerle JK, et al. Choline supplementation in children with fetal
762 alcohol spectrum disorders: a randomized, double-blind, placebo-controlled trial. *Am J Clin*
763 *Nutr.* 2015;102(5):1113-1125. doi:10.3945/ajcn.114.099168
- 764 55. Gimbel BA, Anthony ME, Ernst AM, et al. Long-term follow-up of a randomized controlled
765 trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum
766 white matter microstructure and neurocognitive outcomes. *J Neurodev Disord.*
767 2022;14(1):59. doi:10.1186/s11689-022-09470-w
- 768 56. Mercurio S, Petrillo S, Chiabrando D, et al. The heme exporter Flvcr1 regulates expansion
769 and differentiation of committed erythroid progenitors by controlling intracellular heme
770 accumulation. *Haematologica.* 2015;100(6):720-729. doi:10.3324/haematol.2014.114488
- 771 57. Inoue K, Khajavi M, Ohyama T, et al. Molecular mechanism for distinct neurological
772 phenotypes conveyed by allelic truncating mutations. *Nat Genet.* 2004;36(4):361-369.
773 doi:10.1038/ng1322
- 774 58. Neu-Yilik G, Amthor B, Gehring NH, et al. Mechanism of escape from nonsense-mediated
775 mRNA decay of human β -globin transcripts with nonsense mutations in the first exon. *RNA.*
776 2011;17(5):843-854. doi:10.1261/rna.2401811
- 777
- 778
- 779
- 780
- 781
- 782
- 783

784

785

786

787

788

789

790

791

792

793

794

Table 1: Phenotypic summary of individuals with *FLVCR1*-related developmental and neurodegenerative disorders

	Family 1	Family 2	Family 3	Family 4	Family 5	Family 6		Family 7	Family 8
	Individual 1	Individual 2	Individual 3	Individual 4	Individual 5	Individual 6	Individual 7	Individual 8	Individual 9
Sex, ethnicity	M, S. Asia	M, Middle East	M, European	M, S. Asia	M, North Africa	M, Middle East	M, Middle East	F, S. Asia	F, European
Age at last exam	6-10 yo	0-5 yo	6-10 yo	0-5 yo	0-5 yo	NA	6-10 yo	6-10 yo	0-5 yo
Age at death	NA	0-5 yo	NA	0-5 yo	0-5 yo	0-5 yo	NA	NA	0-5 yo
Nucleotide	c.1390G>A	c.1328T>G	c.1169T>G / c.1261G>A	c.153_154insC	c.915T>G	c.1235G>C ¹	c.1235G>C	c.1390G>A	c.1019C>T / c.1225T>C
Protein	p.G464S	p.L443P	p.L390* / p.D421N	p.A52Rfs*38	p.S305R	p.G412A ¹	p.G412A	p.G464S	p.T340I / p.S409P
Phenotypic category	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD
Microcephaly (Z-score)	+	+	+	+	+	+	+	+	+
	(-2.5)	(-4.2)	(-9.0)	(-6.5)	(-10.5)		(-5.6)	(-4.7)	(-2.9)
DD/ID	Profound	Profound	Profound	Profound	Profound	Profound	Profound	Profound	Profound
Cortical visual impairment	+	-	+	+	+	-	-	-	Unk
Optic disk atrophy	+	+	+	+	+	-	-	-	Unk
Retinitis pigmentosa	-	-	+	-	-	-	-	+	Unk
Hypotonia	+	+	-	+	+	+	+	+	+
Self-mutilation	+	-	-	-	-	-	-	+	-
Osteomyelitis	+	-	-	-	-	-	-	+	-
Sensory neuropathy	+	-	-	-	-	-	-	+	Unk
Motor neuropathy	-	-	-	+	-	-	-	-	Unk
Scoliosis	+	-	+	-	-	-	-	-	Unk
Spasticity	-	+	+	-	+	+	+	-	+
Dystonia	-	-	-	-	+	-	-	-	-
Epilepsy	+	+	+	-	+	+	+	+	Unk
Reduced brain volume	+	+	+	+	+	+	+	+	+
Macrocytic anemia	-	-	-	+	-	-	-	+	Unk
Craniofacial malformations	-	-	-	-	-	-	-	-	-
Limb & digital malformations	-	-	-	+	-	-	-	-	-
Other clinical features			Chorea, myoclonus, pain insensitivity, restrictive LD, neurogenic bladder, severe OSA	Thin corpus callosum, hepatomegaly, preaxial polydactyly, recurrent UTI				Complex IV deficiency on muscle RCE, low CSF 5-MTHF	Laryngomalacia

Abbreviations: NDD, neurodevelopmental disorder; yo, years old; mo, months old; DOL, day of life; DD/ID, developmental delay/intellectual disability; NA, not applicable; ND,

not done; Unk, unknown; LD, lung disease; OSA, obstructive sleep apnea; UTI, urinary tract infections; CSA, central sleep apnea; RCE, respiratory chain enzymes; 5-MTHF – 5-methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.

	Family 8			Family 9			Family 10	Family 11	Family 12
	Individual 10	Individual 11	Individual 12	Individual 13	Individual 14	Individual 15	Individual 16	Individual 17	
Sex, ethnicity	F, European	F, European	F, Middle East	M, Middle East	M, Middle East	F, N. Africa	F, European	M, Middle East	
Age at last exam	0-5 yo	0-5 yo	NA	NA	NA	0-5 yo	0-5 yo	NA	
Age at death	0-5 yo	0-5 yo	Stillborn	Stillborn	Stillborn	0-5 yo	0-5 yo	Neonatal period	
Nucleotide	c.1019C>T / c.1225T>C	c.1019C>T / c.1225T>C	c.1593+5_1593+8del ²	c.1593+5_1593+8del	c.1593+5_1593+8del ²	c.215dupC	c.1198C>T / c.884-3C>G	c.1089T>G	
Protein	p.T340I / p.S409P	p.T340I / p.S409P	p.? ²	p.?	p.? ²	p.E74Rfs*16	p.Q400* / p.?	p.Y363*	
Phenotypic category	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	Severe NDD	
Microcephaly (Z-score)	+ (-6.0)	+ (-3.4)	+	+	+	+ (-3.6)	+ (-3.9)	+	
DD/ID	Profound	Profound	NA	NA	NA	Profound	Profound	NA	
Cortical visual impairment	+	+	NA	NA	NA	-	+	NA	
Optic disk atrophy	+	-	NA	NA	NA	+	+	NA	
Retinitis pigmentosa	Unk	+	NA	NA	NA	-	-	NA	
Hypotonia	+	+	NA	NA	NA	+	+	NA	
Self-mutilation	-	-	NA	NA	NA	-	+	NA	
Osteomyelitis	-	-	NA	NA	NA	-	-	NA	
Sensory neuropathy	Unk	Unk	NA	NA	NA	+	-	NA	
Motor neuropathy	Unk	Unk	NA	NA	NA	+	-	NA	
Scoliosis	+	+	NA	NA	NA	-	+	NA	
Spasticity	+	+	NA	NA	NA	-	-	NA	
Dystonia	+	-	NA	NA	NA	-	+	NA	
Epilepsy	+	+	NA	NA	NA	+	+	NA	
Reduced brain volume	+	+	+	+	+	+	+	+	
Macrocytic anemia	+	+	Unk	Unk	Unk	-	+	Unk	
Craniofacial malformations	-	-	+	+	+	-	-	+	
Limb & digital malformations	-	-	+	+	+	+	+	+	
Other clinical features	Laryngomalacia, hypothyroidism, CSA	Laryngomalacia, OSA, hypothyroidism				Elevated creatine kinase	B cell lymphopenia, anemia, bifid right thumb, bilateral fixed	Hepato-splenomegaly, cardiomegaly, renal agenesis	

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.09.24302464>; this version posted February 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

talipes,
chronic lung
disease

Abbreviations: NDD, neurodevelopmental disorder; yo, years old; mo, months old; DOL, day of life; DD/ID, developmental delay/intellectual disability; NA, not applicable; ND, not done; Unk, unknown; LD, lung disease; OSA, obstructive sleep apnea; UTI, urinary tract infections; CSA, central sleep apnea; RCE, respiratory chain enzymes; 5-MTHF – 5-methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.

	Family 13		Family 14	Family 15	Family 16	Family 17		Family 18	Family 19
	Individual 18	Individual 19	Individual 20	Individual 21	Individual 22	Individual 23	Individual 24	Individual 25	Individual 26
Sex, ethnicity	M, Middle East	F, Middle East	F, N. Africa	M, Middle East	M, Middle East	M, North Africa	M, North Africa	F, Middle East	F, Middle East
Age at last exam	6-10 yo	0-5 yo	11-15 yo	11-15 yo	41-45 yo	6-10 yo	6-10 yo	31-35 yo	0-5 yo
Age at death	NA	NA	NA	NA	NA	NA	NA	NA	NA
Nucleotide	c.1028T>C	c.1028T>C	c.1_18del	c.382T>A	c.382T>A	c.757T>G	c.757T>G	c.502C>G	c.574T>C
Protein	p.I343T	p.I343T	p.M1_D6del	p.Y128N	p.Y128N	p.F253V	p.F253V	p.L168V	p.C192R
Phenotypic category	Mild	Mild	Mild	Mild	Mild	Mild	Mild	Mild	Mild
Microcephaly (Z-score)	-	-	-	-	-	+ (-5.5)	+ (-5.6)	-	-
DD/ID	-	-	Mild ID	-	-	Moderate ID	Severe ID	-	Mild DD
Cortical visual impairment	-	-	-	-	-	-	-	-	-
Optic disk atrophy	-	-	-	-	-	-	-	-	-
Retinitis pigmentosa	-	-	+	+	+	-	-	+	-
Hypotonia	-	-	+	-	+	+	+	-	+
Self-mutilation	-	-	+	-	-	-	-	-	+
Osteomyelitis	-	-	+	-	-	-	-	-	-
Sensory neuropathy	+	+	+	+	-	-	-	+	+
Motor neuropathy	-	-	+	+	+	-	-	-	-
Scoliosis	-	-	-	-	+	-	+	-	-
Spasticity	-	-	-	-	+	-	-	-	-
Dystonia	-	-	-	+	-	-	-	-	-
Epilepsy	-	-	-	-	-	-	+	-	-
Reduced brain volume	ND	ND	-	ND	ND	+	+	ND	ND
Macrocytic anemia	-	-	-	-	-	-	-	-	-
Craniofacial malformations	-	-	-	-	-	-	-	-	-
Limb & digital malformations	-	-	-	-	-	-	-	-	-
Other clinical					Progressive	Dysmorphic	Dysmorphic		

features					spastic paraplegia, childhood onset	facies, autistic features	facies, autistic features, cryptorchidism		
Abbreviations: NDD, neurodevelopmental disorder; yo, years old; mo, months old; DOL, day of life; DD/ID, developmental delay/intellectual disability; NA, not applicable; NR, not reported; ND, not done; Unk, unknown; LD, lung disease; OSA, obstructive sleep apnea; UTI, urinary tract infections; CSA, central sleep apnea; RCE, respiratory chain enzymes; 5-MTHF – 5-methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.									

	Family 20	Severe NDD
	Individual 27	summary
Sex, ethnicity	F, Middle East	
Age at last exam	66-70 yo	
Age at death	NA	13/17
Nucleotide	c.1028T>C	
Protein	p.I343T	
Phenotypic category	Mild	
Microcephaly (Z-score)	-	17/17
DD/ID	-	13/13
Cortical visual impairment	-	7/12
Optic disk atrophy	-	8/12
Retinitis pigmentosa	+	3/12
Hypotonia	-	12/13
Self-mutilation	-	3/12
Osteomyelitis	-	2/12
Sensory neuropathy	-	3/10
Motor neuropathy	-	2/10
Scoliosis	-	5/12
Spasticity	-	8/13
Dystonia	+	3/13
Epilepsy	-	11/12
Reduced brain volume	-	17/17
Macrocytic anemia	-	5/12
Craniofacial malformations	-	4/17
Limb & digital malformations	-	7/17
Other clinical features		
Abbreviations: NDD, neurodevelopmental disorder; yo, years old; mo, months old; DOL, day of life; DD/ID, developmental delay/intellectual disability; NA, not		


applicable; ND, not done; Unk, unknown; LD, lung disease; OSA, obstructive sleep apnea; UTI, urinary tract infections; CSA, central sleep apnea; RCE, respiratory chain enzymes; 5-MTHF – 5-methyltetrahydrofolate; 1,2 – patient DNA not available for genotyping but felt to have same condition.

Table 2: Summary of *FLVCR1* variant alleles

Individual(s)	Phenotype	Zygoty	Position (hg19)	Nucleotide / Protein	Allele count / frequency (gnomAD)	CADD	REVEL	phyloP100 way	SpliceAI
F1, I-1; F7, I-8	Severe	Hmz	1-213061913-G-A	c.1390G>A p.G464S	1 htz 1 in 251,426	33	0.742	9.242	0.17 (donor gain), 0.23 (donor loss)
F2, I-2	Severe	Hmz	1-213061851-T-G	c.1328T>G p.L443P	0	31	0.757	7.546	0.11 (donor gain)
F3, I-3	Severe	Cmp htz	1-213058711-T-G	c.1169T>G p.L390*	0	37	-	7.546	0
	Severe	Cmp htz	1-213061297-G-A	c.1261G>A p.D421N	0	16.72	0.087	-0.223	0.22 (donor loss)
F4, I-4	Severe	Hmz	1-213031948--C	c.153_154insC p.A52Rfs*38	0	-	-	5.239	-
F5, I-5	Severe	Hmz	1-213046051-T-G	c.915T>G p.S305R	0	23.1	0.486	0.23	0
F6, I-7	Severe	Hmz	1-213061271-G-C	c.1235G>C p.G412A	2 htz 1 in 125,477	29.8	0.435	4.104	0.11 (acceptor gain), 0.28 (acceptor loss)
F8, I-9, I-10, I-11	Severe	Cmp htz	1-213046155-C-T	c.1019C>T p.T340I	2 htz 1 in 125,435	22.5	0.281	0.814	0
	Severe	Cmp htz	1-213061261-T-C	c.1225C>T p.S409P	0	29.5	0.624	5.727	0.19 (acceptor gain)
F9, I-12 ^a , I-13, I-14 ^a	Severe	Hmz	1-213068396-GTAA-	c.1593+5_1593+8del, p.?	9 htz 1 in 27,874	-	-	7.236	0.97 (donor loss)
F10, I-15	Severe	Hmz	1-213032009--C	c.215dupC, p.E74Rfs*16	0	-	-	5.549	-
F11, I-16	Severe	Cmp htz	1-213061234-C-T	c.1198C>T p.Q400*	0	47	-	3.853	0
		Cmp htz	1-213046017-C-G	c.884-3C>G p.?	0	17.84	-	0.123	0.43 (acceptor loss), 0.09 (acceptor gain)
F12, I-7	Severe	Hmz	1-213056777-T-G	c.1089T>G p.Y363*	0	34	-	0.449	0.02 (donor loss)
F13, I-18, I-19; F20, I-27	Mild	Hmz	1-213056716-T-C	c.1028T>C p.I343T	1 htz 1 in 242,226	26.9	0.525	6.637	0
F14, I-20	Mild	Hmz	1-213031792- GATATGGCGCGGCCAGAC-	c.1_18del p.?	0	-	-	3.118	-
F15, I-21; F16, I-22	Mild	Hmz	1-213032176-T-A	c.382T>A p.Y128N	0	32	0.723	7.629	0
F17, I-23, I-24	Mild	Hmz	1-213037085-T-G	c.757T>G p.F253V	0	29.8	0.718	7.806	0
F18, I-25	Mild	Hmz	1-213032296-C-G	c.502C>G p.L168V	0	26.0	0.34	3.743	0
F19, I-26	Mild	Hmz	1-213032368-T-C	c.574T>C p.C192R	5 htz 1 in 50,112	29.3	0.895	1.93	0

Abbreviations: CADD, Combined Annotation Dependent Depletion GRCh37-v1.6; gnomAD, Genome Aggregation Database v2.1.1; hmz, homozygote; cmp htz, compound heterozygote; REVEL, rare exome variant ensemble learner; a – patient DNA not available for genotyping but felt to have same condition.

Fig. 2



A) FLVCR1 cDNA NM_014053.4

Fig. 3

Start loss variants

c.2T>C, c.1_18del
c.3G>T

Splice variants

c.883+6T>C
c.884-3C>G


c.1092+5G>A

c.1593+5_1593+8del




B)

ESM1b FLVCR1 predictions



FLVCR1 protein Q9Y5Y0



C)


CADD

REVEL

MetaRNN

phyloP100way

GERP



D)

CADD

REVEL

GERP

TM 9-11 clustering

Isoform clustering




Fig. 4

